格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Summary by Category - **Share Reduction** - Morgan Stanley sold 798,119 shares of WuXi AppTec [1] - The sale price was HKD 109.1481 per share [1] - The total amount from the sale was approximately HKD 87.1132 million [1] - **Current Holdings** - After the reduction, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million [1] - The new ownership percentage is 6.90% [1]

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by selling 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Group 1 - Morgan Stanley sold 798,119 shares of WuXi AppTec on February 3 [1] - The selling price per share was HKD 109.1481, leading to a total transaction value of approximately HKD 87.1132 million [1] - After the sale, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million, which constitutes a 6.90% ownership stake [1]

证券日报网讯 2月6日，药明康德（603259）在互动平台回答投资者提问时表示，2025年前三季度，公 司来自欧洲客户收入为38.4亿元，占公司持续经营业务收入的12%。 ...

（文章来源：证券日报） 证券日报网讯 2月6日，药明康德在互动平台回答投资者提问时表示，公司历来不自行开发新药，也没 有用AI来开发新药。 ...

Core Viewpoint - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. Group 1: Company Overview - WuXi AppTec is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest companies engaged in integrated CRO (Contract Research Organization) and CMO (Contract Manufacturing Organization) services [2]. - The company has a high-level management team with over 200 authorized and pending patent achievements [2]. - Its main business involves the discovery, research, and production of small molecule chemical drugs, offering a full range of integrated platform services to global pharmaceutical companies [2][7]. Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [7]. - The net profit attributable to the parent company was 12.076 billion yuan, showing a significant year-on-year increase of 84.84% [7]. - The company has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8]. Group 3: Market Position and Trends - As of February 6, the stock price of WuXi AppTec increased by 0.74%, with a trading volume of 3.438 billion yuan and a turnover rate of 1.42%, leading to a total market capitalization of 291.901 billion yuan [1]. - The company benefits from a high overseas revenue ratio of 78.67%, which is positively impacted by the depreciation of the Chinese yuan [3]. - The average trading cost of the stock is 97.44 yuan, with the stock price approaching a resistance level of 98.02 yuan, indicating potential for upward movement if this level is surpassed [6].

高盛 公司将 药明康德 A股评级上调至买进；目标价132.70元人民币。 ...

Core Viewpoint - The Hong Kong biotechnology sector is experiencing a significant upward trend, with notable gains in various stocks, indicating positive market sentiment in the industry [1] Group 1: Stock Performance - Nocare Biopharma (09969.HK) has seen an increase of over 4% [1] - Other companies such as Zai Lab (09688.HK), WuXi AppTec (02359.HK), WuXi Biologics (02269.HK), and Innovent Biologics (02696.HK) are also witnessing upward movement in their stock prices [1]

Core Viewpoint - WuXi AppTec is experiencing growth due to its position as a leading Contract Research Organization (CRO) and its benefits from the depreciation of the Renminbi, with a significant portion of its revenue coming from overseas markets [2][3]. Company Overview - WuXi AppTec is an international leader in providing integrated new drug research and production services for the global biopharmaceutical industry, focusing on small molecule chemical drug discovery, development, and production [2]. - The company has a comprehensive platform service model that caters to global pharmaceutical companies, including medical device testing and precision medical research and production services abroad [2]. - As of September 30, 2025, WuXi AppTec reported a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit of 12.076 billion yuan, with an impressive growth of 84.84% [7]. Financial Performance - The company’s overseas revenue accounted for 78.67% of its total revenue, benefiting from the depreciation of the Renminbi [3]. - The main business revenue composition includes chemical business (78.37%), testing business (12.93%), biological business (6.02%), and other services [7]. - WuXi AppTec has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8]. Market Activity - On February 4, the stock price of WuXi AppTec increased by 1.07%, with a trading volume of 3.14 billion yuan and a turnover rate of 1.34%, leading to a total market capitalization of 285.277 billion yuan [1]. - The stock has seen a net inflow of 118 million yuan from major investors, indicating a positive sentiment in the market [4][5].